Dendritic cells, indoleamine 2,3 dioxygenase and acquired immune privilege

Lei Huang, Babak Baban, Burles A. Johnson, Andrew L. Mellor

Research output: Contribution to journalReview article

75 Citations (Scopus)

Abstract

Dendritic cells (DCs) are specialized to stimulate T cell immunity. Paradoxically, some DCs suppress T cell responses and activate regulatory T cells. In this review, we focus on a potent counter-regulatory pathway mediated by plasmacytoid DCs (pDCs) expressing the immunosuppressive enzyme indoleamine 2,3 dioxygenase (IDO). IDO-expressing pDCs inhibit effector T cell responses, activate regulatory T cells, and attenuate pro-inflammatory responses in settings of chronic inflammation that manifest in clinical syndromes, such as infectious, allergic, and autoimmune diseases; cancer; and transplantation. Thus, IDO-expressing pDCs create immune privilege and provide novel opportunities to improve immunotherapy in multiple disease syndromes.

Original languageEnglish (US)
Pages (from-to)133-155
Number of pages23
JournalInternational Reviews of Immunology
Volume29
Issue number2
DOIs
StatePublished - Mar 1 2010

Fingerprint

Indoleamine-Pyrrole 2,3,-Dioxygenase
Dendritic Cells
Regulatory T-Lymphocytes
T-Lymphocytes
Immunosuppressive Agents
Immunotherapy
Autoimmune Diseases
Communicable Diseases
Immunity
Transplantation
Inflammation
Enzymes
Neoplasms

Keywords

  • Dendritic cells
  • Indoleamine 2,3 dioxygenase
  • Regulation
  • T cells

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Dendritic cells, indoleamine 2,3 dioxygenase and acquired immune privilege. / Huang, Lei; Baban, Babak; Johnson, Burles A.; Mellor, Andrew L.

In: International Reviews of Immunology, Vol. 29, No. 2, 01.03.2010, p. 133-155.

Research output: Contribution to journalReview article

Huang, Lei ; Baban, Babak ; Johnson, Burles A. ; Mellor, Andrew L. / Dendritic cells, indoleamine 2,3 dioxygenase and acquired immune privilege. In: International Reviews of Immunology. 2010 ; Vol. 29, No. 2. pp. 133-155.
@article{8baff7c1da394eda86d0f853801a22ac,
title = "Dendritic cells, indoleamine 2,3 dioxygenase and acquired immune privilege",
abstract = "Dendritic cells (DCs) are specialized to stimulate T cell immunity. Paradoxically, some DCs suppress T cell responses and activate regulatory T cells. In this review, we focus on a potent counter-regulatory pathway mediated by plasmacytoid DCs (pDCs) expressing the immunosuppressive enzyme indoleamine 2,3 dioxygenase (IDO). IDO-expressing pDCs inhibit effector T cell responses, activate regulatory T cells, and attenuate pro-inflammatory responses in settings of chronic inflammation that manifest in clinical syndromes, such as infectious, allergic, and autoimmune diseases; cancer; and transplantation. Thus, IDO-expressing pDCs create immune privilege and provide novel opportunities to improve immunotherapy in multiple disease syndromes.",
keywords = "Dendritic cells, Indoleamine 2,3 dioxygenase, Regulation, T cells",
author = "Lei Huang and Babak Baban and Johnson, {Burles A.} and Mellor, {Andrew L.}",
year = "2010",
month = "3",
day = "1",
doi = "10.3109/08830180903349669",
language = "English (US)",
volume = "29",
pages = "133--155",
journal = "International Reviews of Immunology",
issn = "0883-0185",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Dendritic cells, indoleamine 2,3 dioxygenase and acquired immune privilege

AU - Huang, Lei

AU - Baban, Babak

AU - Johnson, Burles A.

AU - Mellor, Andrew L.

PY - 2010/3/1

Y1 - 2010/3/1

N2 - Dendritic cells (DCs) are specialized to stimulate T cell immunity. Paradoxically, some DCs suppress T cell responses and activate regulatory T cells. In this review, we focus on a potent counter-regulatory pathway mediated by plasmacytoid DCs (pDCs) expressing the immunosuppressive enzyme indoleamine 2,3 dioxygenase (IDO). IDO-expressing pDCs inhibit effector T cell responses, activate regulatory T cells, and attenuate pro-inflammatory responses in settings of chronic inflammation that manifest in clinical syndromes, such as infectious, allergic, and autoimmune diseases; cancer; and transplantation. Thus, IDO-expressing pDCs create immune privilege and provide novel opportunities to improve immunotherapy in multiple disease syndromes.

AB - Dendritic cells (DCs) are specialized to stimulate T cell immunity. Paradoxically, some DCs suppress T cell responses and activate regulatory T cells. In this review, we focus on a potent counter-regulatory pathway mediated by plasmacytoid DCs (pDCs) expressing the immunosuppressive enzyme indoleamine 2,3 dioxygenase (IDO). IDO-expressing pDCs inhibit effector T cell responses, activate regulatory T cells, and attenuate pro-inflammatory responses in settings of chronic inflammation that manifest in clinical syndromes, such as infectious, allergic, and autoimmune diseases; cancer; and transplantation. Thus, IDO-expressing pDCs create immune privilege and provide novel opportunities to improve immunotherapy in multiple disease syndromes.

KW - Dendritic cells

KW - Indoleamine 2,3 dioxygenase

KW - Regulation

KW - T cells

UR - http://www.scopus.com/inward/record.url?scp=77952508328&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952508328&partnerID=8YFLogxK

U2 - 10.3109/08830180903349669

DO - 10.3109/08830180903349669

M3 - Review article

C2 - 20367139

AN - SCOPUS:77952508328

VL - 29

SP - 133

EP - 155

JO - International Reviews of Immunology

JF - International Reviews of Immunology

SN - 0883-0185

IS - 2

ER -